In vitro metabolic fate of 1-[3-(trimethylsilyl)propanoyl] lysergic acid diethylamide (1S-LSD), a silicon-containing LSD analog
Forensic Toxicology · 2026
DOI: 10.1007/s11419-025-00735-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Forensic Toxicology, 2026. Verfasst von Yuki Azuma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hygienic Chemistry, Osaka Institute of Public Health, 1-3-3 Nakamichi, Higashinari-Ku, Osaka, 537-0025, Japan. azumay@iph.osaka.jp. Hauptthemen laut MEDLINE: Lysergic Acid Diethylamide, Microsomes, Liver, Hallucinogens. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
PURPOSE: A new lysergic acid diethylamide (LSD) analog has recently been identified, 1-[3-(Trimethylsilyl)propanoyl] LSD (1S-LSD), characterized by a silicon-containing acyl moiety. In the proof of LSD analog consumption, direct detection of the parent compound in urine or blood can be challenging; therefore, characteristic metabolites as consumption markers should be detected. However, the metabolic fate is unclear. This study aimed to characterize the metabolic properties of 1S-LSD. METHODS: The synthesized 1S-LSD was incubated with human liver microsomes. The obtained metabolites were analyzed using liquid chromatography-quadrupole time-of-flight mass spectrometry. RESULTS: The parent compound was metabolized at a moderately rapid rate, with the early formation of LSD. Sixty-two metabolites were observed, and a metabolic pathway was proposed. The major metabolites were compounds with hydroxyl groups in the 3-silylpropanoyl moiety. Five metabolites were relatively abundant and retained their 3-silylpropanoyl moieties: N-deethylated 1S-LSD (Si04), N-deethylated and silanolized 1S-LSD (Si06), N-deethylated and monohydroxylated 1S-LSD (Si09 and Si11), and silanolized 1S-LSD (Si21). CONCLUSIONS: The metabolic fate of 1S-LSD, an abused drug containing silicon, was characterized for the first time. The diverse metabolic pathways will help better understand the metabolic processes of not only 1S-LSD but also N1-acylated LSD analogs and compounds with trimethylsilyl groups. Si04, Si06, Si09, Si11, and Si21 are potential target analytes for proving 1S-LSD consumption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hygienic Chemistry, Osaka Institute of Public Health, 1-3-3 Nakamichi, Higashinari-Ku, Osaka, 537-0025, Japan. azumay@iph.osaka.jp.
- Division of Hygienic Chemistry, Osaka Institute of Public Health, 1-3-3 Nakamichi, Higashinari-Ku, Osaka, 537-0025, Japan.
ORCID-Profile: Yuki Azuma
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Azuma, Y., Tanaka, M., Asada, A., & Doi, T. (2026). In vitro metabolic fate of 1-[3-(trimethylsilyl)propanoyl] lysergic acid diethylamide (1S-LSD), a silicon-containing LSD analog. Forensic Toxicology. https://doi.org/10.1007/s11419-025-00735-2
Vancouver
Azuma Y, Tanaka M, Asada A, Doi T. In vitro metabolic fate of 1-[3-(trimethylsilyl)propanoyl] lysergic acid diethylamide (1S-LSD), a silicon-containing LSD analog. Forensic Toxicology. 2026. doi:10.1007/s11419-025-00735-2
BibTeX
@article{Azuma2026,
author = {Azuma, Yuki and Tanaka, Misa and Asada, Akiko and Doi, Takahiro},
title = {In vitro metabolic fate of 1-[3-(trimethylsilyl)propanoyl] lysergic acid diethylamide (1S-LSD), a silicon-containing LSD analog},
journal = {Forensic Toxicology},
year = {2026},
doi = {10.1007/s11419-025-00735-2}
}
EUVIMED